頁籤選單縮合
| 題 名 | 免疫檢查點抑制劑引起irAE探討=Immune-related Adverse Event of Immune Checkpoint Inhibitor |
|---|---|
| 作 者 | 陳宜正; 鄭吉元; 蔡慈貞; | 書刊名 | 藥學雜誌 |
| 卷 期 | 35:3=140 2019.09[民108.09] |
| 頁 次 | 頁100-104 |
| 分類號 | 418.29 |
| 關鍵詞 | 免疫檢查點抑制劑; 免疫相關副作用; Immune checkpoint inhibitor; ICPi; Immune-related adverse event; irAE; |
| 語 文 | 中文(Chinese) |
| 中文摘要 | 近幾年癌症免疫療法的快速發展為癌症治療開啟新頁,其中最受矚目且應用最 廣的莫過於免疫檢查點抑制劑 (immune checkpoint inhibitor,ICPi),包括 CTLA-4與 PD-1/PD-L1抑制劑。此類藥物透過調控人體既有的免疫機制來達到毒殺癌細胞之效 果,目前臨床上已用於治療黑色素瘤、肺癌、腎細胞癌、淋巴癌、胃癌、肝癌、大腸 直腸癌與泌尿道癌等疾病。對於進展快速且難以治癒之癌症如黑色素瘤,部分病人使 用免疫檢查點抑制劑後能產生明顯而且持久的療效,醫界因此大受鼓舞,紛紛投入相 關研究與產品開發。然而,新藥物也與以往使用化療藥物發生迥異的免疫相關副作用 (immune-related adverse event,irAE),雖然大部分的 irAE 都是可恢復的,但仍有少數 病人會引起嚴重的 irAE 甚至導致死亡,因此及早辨識與適當處置 irAE 是一門相當重 要的課題。本文將探討 ICPi 常見或重要的 irAE,以及在發生 irAE 時如何處理。 |
| 英文摘要 | Immune checkpoint inhibitors such as CTLA-4 and PD-1/PD-L1 blockade have been in the limelight among several cancer immunotherapies during the last few years. These drugs augment the immunologic reaction against tumor cells in several cancer types including melanoma, lung cancer, renal cell carcinoma, lymphoma, gastric cancer, hepatocellular carcinoma, colorectal cancer and urothelial carcinoma. Immune checkpoint blockade has shown remarkable benefit and durable response in the treatment of advanced melanoma. However, the new category of medication has led to a different spectrum of dysimmune toxicity termed immune-related adverse event (irAE). Although most irAE could be manageable, serious and even fatal irAE still happened in few cases; hence, early diagnosis and proper management of the irAE are a very important issue. This article will discuss common or notable irAE, and how to deal with irAE. |
本系統中英文摘要資訊取自各篇刊載內容。